Singulex, a diagnostics company based in Alameda, CA, has filed for an $86.25 million IPO. According to the San Francisco Business Times, the company promises a test that can measure previously undetectable levels of cytokines, blood biomarkers that could indicate an increased risk of heart attack. The company is designing and developing a second-generation digital immunoassay monitoring platform, which could come into use in its own laboratories in 2014, and be commercially available by 2016. Nasdaq overview | Article